FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: US Committee Launches Probe Against Five Drugmakers over China Clinical Trials

By

A US congressional committee on China has launched investigations into whether five major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities, according to a Reuters report on Tuesday, citing sources.

The chair of the U.S. House Select Committee ​on China opened national security investigations into drugmakers, including Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb, the report said.

According to letters quoted in the report, the inquiry focuses on due diligence, data protection, and trial locations, including sensitive sites like Xinjiang and military hospitals. Republican Representative John Moolenaar of Michigan has asked for details of the due diligence by July 17.

The five mentioned drug companies, Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb, did not immediately respond to' request for a comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Duketon Mining's Geochemical Targeting Method Proving Effective, Applied to Around 30% of Granted Tenure, Euroz Hartleys Says

Duketon Mining's (ASX:DKM) geochemical targeting method is proving effective but has only been applied to around 30% of the granted tenure, indicating potential for further discovery, Euroz Hartleys said in a Wednesday note.The firm's drilling program at the Barlee gold project in Western Australia confirmed consistent, shallow gold mineralization across multiple prospects, with Gromit delivering the strongest result of 30 meters at 1.1 grams-per-tonne grade of gold from 12 meters. Mineralization remained open in all directions.Strong mergers and acquisition activity in the Southern Cross district, led by Forrestania Resources' (ASX:FRS) consolidation strategy, highlighted Barlee's strategic position and underscores the potential for future discoveries.The investment firm retained its speculative buy recommendation and AU$0.75 per share price target on Duketon Mining.

ASX:DKMASX:FRS
Asia

Native Mineral Resources Says Unit Lodges Progressive Rehabilitation, Closure Plan for Queensland Project; Shares Up 8%

Native Mineral Resources (ASX:NMR) said its Fortified Gold unit successfully lodged a progressive rehabilitation and closure plan (PRCP) for its Far Fanning gold project in Queensland with the Queensland Department of the Environment, according to a Wednesday Australian bourse filing.The submission follows the commencement of the Queensland Environmental Protection and Other Legislation Amendment Act 2026, which was assented to on June 16.The company said the legislative amendment provides a clearer regulatory pathway by allowing eligible environmentally relevant activities to continue under an existing environmental authority. At the same time, a PRCP is being assessed, the filing added.Current drilling at Far Fanning is expected to further improve geological confidence and support future resource updates, with NMR also expecting to submit a PRCP for the Blackjack Gold Mine within the coming days, it added.The company's shares rose almost 8% in recent Wednesday trade.

ASX:NMR
Asia

ASTI Holdings Receives First Tranche of Settlement Payment; Shares Up 3%

ASTI Holdings (SGX:575) received the first installment of a settlement payment of SG$300,000 from Advanced Systems Automation (SGX:WJ9), according to a Tuesday filing with the Singapore Exchange.Shares of the semiconductor company were up over 3% in Wednesday trading.Earlier, the company had signed new terms with Advanced Systems, with the latter making a payment of SG$300,000 to ASTI by July 1 and the remaining balance of SG$700,000 by Aug. 1, instead of paying them in full by July 1.

SGX:575